EU Pilot Shows Single Drug Development Plan Can Meet Both Regulator And HTA Needs
This article was originally published in SRA
Executive Summary
The EU's pilot exercise in offering drug developers parallel regulatory and health technology assessment (HTA) advice has shown that in most cases a single trial design or drug development plan can be agreed that meets the requirements of the two parties without blurring their respective remits, says a new report from the European Medicines Agency1.
You may also be interested in...
Single Gateway For EMA-HTA Advice May Answer All Stakeholders’ Needs
The EU research-based pharmaceutical industry has welcomed the launch of a new single gateway for companies to seek parallel scientific advice from the European Medicines Agency and health technology assessment bodies on initial evidence generation and post-authorization data collection. The industry hopes the initiative will help deliver one single evidence package for regulatory and HTA purposes.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.